PHIP and prostate carcinoma: Although used in only a few epidemiological studies so far, PhIP-DNA adducts were shown to be not significantly but rather only modestly associated with an increased risk of prostate cancer among 534 nested case-control pairs within a historical cohort of men with a benign prostate specimen in the US [32].